A peptide derived from melanotransferrin delivers a protein-based interleukin 1 receptor antagonist across the BBB and ameliorates neuropathic pain in a preclinical model

George Thom, Mei Mei Tian, Jon P. Hatcher, Natalia Rodrigo, Matthew Burrell, Ian Gurrell, Timothy Z. Vitalis, Thomas Abraham, Wilfred A. Jefferies, Carl I. Webster, Reinhard Gabathuler

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Delivery of biologic drugs across the blood–brain barrier is becoming a reality. However, the solutions often involve the assembly of complex multi-specific antibody molecules. Here we utilize a simple 12 amino-acid peptide originating from the melanotransferrin (MTf) protein that has shown improved brain delivery properties. 3D confocal fluorescence microscopic analysis demonstrated brain parenchymal localisation of a fluorescently labelled antibody (NIP228) when chemically conjugated to either the MTf peptide or full-length MTf protein. Measurement of plasma kinetics demonstrated the MTf peptide fusions had very similar kinetics to an unmodified NIP228 control antibody, whereas the fusion to MTf protein had significantly reduced plasma exposure most likely due to a higher tissue distribution in the periphery. Brain exposure for the MTf peptide fusions was significantly increased for the duration of the study, exceeding that of the fusions to full length MTf protein. Using a neuropathic pain model, we have demonstrated that fusions to interleukin-1 receptor antagonist (IL-1RA) are able to induce significant and durable analgesia following peripheral administration. These data demonstrate that recombinant and chemically conjugated MTf-based brain delivery vectors can deliver therapeutic levels of drug to the central nervous system.

Original languageEnglish (US)
Pages (from-to)2074-2088
Number of pages15
JournalJournal of Cerebral Blood Flow and Metabolism
Volume39
Issue number10
DOIs
StatePublished - Oct 1 2019

Fingerprint

Interleukin 1 Receptor Antagonist Protein
Neuralgia
Peptides
Brain
Antibodies
Proteins
Central Nervous System Agents
Interleukin-1 Receptors
Tissue Distribution
Analgesia
Fluorescence
Amino Acids
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine

Cite this

Thom, George ; Tian, Mei Mei ; Hatcher, Jon P. ; Rodrigo, Natalia ; Burrell, Matthew ; Gurrell, Ian ; Vitalis, Timothy Z. ; Abraham, Thomas ; Jefferies, Wilfred A. ; Webster, Carl I. ; Gabathuler, Reinhard. / A peptide derived from melanotransferrin delivers a protein-based interleukin 1 receptor antagonist across the BBB and ameliorates neuropathic pain in a preclinical model. In: Journal of Cerebral Blood Flow and Metabolism. 2019 ; Vol. 39, No. 10. pp. 2074-2088.
@article{ad607a72cd0e42e2839c2e39003796b5,
title = "A peptide derived from melanotransferrin delivers a protein-based interleukin 1 receptor antagonist across the BBB and ameliorates neuropathic pain in a preclinical model",
abstract = "Delivery of biologic drugs across the blood–brain barrier is becoming a reality. However, the solutions often involve the assembly of complex multi-specific antibody molecules. Here we utilize a simple 12 amino-acid peptide originating from the melanotransferrin (MTf) protein that has shown improved brain delivery properties. 3D confocal fluorescence microscopic analysis demonstrated brain parenchymal localisation of a fluorescently labelled antibody (NIP228) when chemically conjugated to either the MTf peptide or full-length MTf protein. Measurement of plasma kinetics demonstrated the MTf peptide fusions had very similar kinetics to an unmodified NIP228 control antibody, whereas the fusion to MTf protein had significantly reduced plasma exposure most likely due to a higher tissue distribution in the periphery. Brain exposure for the MTf peptide fusions was significantly increased for the duration of the study, exceeding that of the fusions to full length MTf protein. Using a neuropathic pain model, we have demonstrated that fusions to interleukin-1 receptor antagonist (IL-1RA) are able to induce significant and durable analgesia following peripheral administration. These data demonstrate that recombinant and chemically conjugated MTf-based brain delivery vectors can deliver therapeutic levels of drug to the central nervous system.",
author = "George Thom and Tian, {Mei Mei} and Hatcher, {Jon P.} and Natalia Rodrigo and Matthew Burrell and Ian Gurrell and Vitalis, {Timothy Z.} and Thomas Abraham and Jefferies, {Wilfred A.} and Webster, {Carl I.} and Reinhard Gabathuler",
year = "2019",
month = "10",
day = "1",
doi = "10.1177/0271678X18772998",
language = "English (US)",
volume = "39",
pages = "2074--2088",
journal = "Journal of Cerebral Blood Flow and Metabolism",
issn = "0271-678X",
publisher = "Nature Publishing Group",
number = "10",

}

A peptide derived from melanotransferrin delivers a protein-based interleukin 1 receptor antagonist across the BBB and ameliorates neuropathic pain in a preclinical model. / Thom, George; Tian, Mei Mei; Hatcher, Jon P.; Rodrigo, Natalia; Burrell, Matthew; Gurrell, Ian; Vitalis, Timothy Z.; Abraham, Thomas; Jefferies, Wilfred A.; Webster, Carl I.; Gabathuler, Reinhard.

In: Journal of Cerebral Blood Flow and Metabolism, Vol. 39, No. 10, 01.10.2019, p. 2074-2088.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A peptide derived from melanotransferrin delivers a protein-based interleukin 1 receptor antagonist across the BBB and ameliorates neuropathic pain in a preclinical model

AU - Thom, George

AU - Tian, Mei Mei

AU - Hatcher, Jon P.

AU - Rodrigo, Natalia

AU - Burrell, Matthew

AU - Gurrell, Ian

AU - Vitalis, Timothy Z.

AU - Abraham, Thomas

AU - Jefferies, Wilfred A.

AU - Webster, Carl I.

AU - Gabathuler, Reinhard

PY - 2019/10/1

Y1 - 2019/10/1

N2 - Delivery of biologic drugs across the blood–brain barrier is becoming a reality. However, the solutions often involve the assembly of complex multi-specific antibody molecules. Here we utilize a simple 12 amino-acid peptide originating from the melanotransferrin (MTf) protein that has shown improved brain delivery properties. 3D confocal fluorescence microscopic analysis demonstrated brain parenchymal localisation of a fluorescently labelled antibody (NIP228) when chemically conjugated to either the MTf peptide or full-length MTf protein. Measurement of plasma kinetics demonstrated the MTf peptide fusions had very similar kinetics to an unmodified NIP228 control antibody, whereas the fusion to MTf protein had significantly reduced plasma exposure most likely due to a higher tissue distribution in the periphery. Brain exposure for the MTf peptide fusions was significantly increased for the duration of the study, exceeding that of the fusions to full length MTf protein. Using a neuropathic pain model, we have demonstrated that fusions to interleukin-1 receptor antagonist (IL-1RA) are able to induce significant and durable analgesia following peripheral administration. These data demonstrate that recombinant and chemically conjugated MTf-based brain delivery vectors can deliver therapeutic levels of drug to the central nervous system.

AB - Delivery of biologic drugs across the blood–brain barrier is becoming a reality. However, the solutions often involve the assembly of complex multi-specific antibody molecules. Here we utilize a simple 12 amino-acid peptide originating from the melanotransferrin (MTf) protein that has shown improved brain delivery properties. 3D confocal fluorescence microscopic analysis demonstrated brain parenchymal localisation of a fluorescently labelled antibody (NIP228) when chemically conjugated to either the MTf peptide or full-length MTf protein. Measurement of plasma kinetics demonstrated the MTf peptide fusions had very similar kinetics to an unmodified NIP228 control antibody, whereas the fusion to MTf protein had significantly reduced plasma exposure most likely due to a higher tissue distribution in the periphery. Brain exposure for the MTf peptide fusions was significantly increased for the duration of the study, exceeding that of the fusions to full length MTf protein. Using a neuropathic pain model, we have demonstrated that fusions to interleukin-1 receptor antagonist (IL-1RA) are able to induce significant and durable analgesia following peripheral administration. These data demonstrate that recombinant and chemically conjugated MTf-based brain delivery vectors can deliver therapeutic levels of drug to the central nervous system.

UR - http://www.scopus.com/inward/record.url?scp=85047952906&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047952906&partnerID=8YFLogxK

U2 - 10.1177/0271678X18772998

DO - 10.1177/0271678X18772998

M3 - Article

C2 - 29845881

AN - SCOPUS:85047952906

VL - 39

SP - 2074

EP - 2088

JO - Journal of Cerebral Blood Flow and Metabolism

JF - Journal of Cerebral Blood Flow and Metabolism

SN - 0271-678X

IS - 10

ER -